Details of the Drug

General Information of Drug (ID: DMZ7XNQ)

• Drug Name: Tacrolimus
• Synonyms: Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN

Indication

Disease Entry	ICD 11	Status	REF
Graft-versus-host disease	4B24	Approved	[1]
Hepatosplenic T-cell lymphoma	N.A.	Approved	[1]
Kidney transplant rejection	NE84	Approved	[1]
Large granular lymphocytic leukemia	2A90.1	Approved	[1]
Leukemia	N.A.	Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[1]
MALT lymphoma	N.A.	Approved	[1]
Myeloproliferative neoplasm	2A20	Approved	[1]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Organ transplant rejection	NE84	Approved	[2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[1]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[1]
Small intestine lymphoma	N.A.	Approved	[1]
Splenic marginal zone lymphoma	N.A.	Approved	[1]
Testicular lymphoma	N.A.	Approved	[1]
Ocular allergy	4A81	Phase 3	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]

• Therapeutic Class: Immunosuppressive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 804
  Logarithm of the Partition Coefficient (xlogp); 2.7
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 12
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.7 mL/min/kg [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 35 hours (in adult healthy volunteers), 19 hours (in kidney transplant patients), 12 hours (in liver transplants patients), and 24 hours (in heart transplant patients) [4]
  Metabolism: The drug is metabolized via the CYP3A4 and secondarily by CYP3A5 [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.24329 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [4]
  Vd: The volume of distribution (Vd) of drug is 2.6 +/- 2.1 L/kg []
  Water Solubility: The ability of drug to dissolve in water is measured as 0.008 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Nephropathy toxic	Not Available	PPP3R1	OTGQNFJQ	[7]

• Chemical Identifiers:
  Formula: C44H69NO12
  IUPAC Name: (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
  Canonical SMILES: C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
  InChI: InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
  InChIKey: QJJXYPPXXYFBGM-LFZNUXCKSA-N
• Cross-matching ID:
  PubChem CID: 445643
  ChEBI ID: CHEBI:61049
  CAS Number: 104987-11-3
  DrugBank ID: DB00864
  TTD ID: D06OMK
  VARIDT ID: DR00406
  INTEDE ID: DR1524
  ACDINA ID: D00648
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcineurin (PPP3CA)	TTA4LDE	PP2BA_HUMAN	Inhibitor	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]
NADPH-cytochrome P450 reductase (CPR)	DE3N2FM	NCPR_HUMAN	Substrate	[12]
Ribosomal 23S RNA methyltransferase Erm (erm)	DEW6V07	A0A5N1AHF6_CORAY	Substrate	[13]
Ribosomal 23S RNA methyltransferase Erm (erm)	DEA65D8	A0A381KDL2_CORJE	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Actin-related protein 2/3 complex subunit 5 (ARPC5)	OTFNMMDL	ARPC5_HUMAN	Gene/Protein Processing	[14]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[15]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[16]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[17]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[18]
C-C chemokine receptor type 3 (CCR3)	OT6GBUFA	CCR3_HUMAN	Gene/Protein Processing	[19]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Gene/Protein Processing	[19]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Gene/Protein Processing	[20]
Calcineurin subunit B type 1 (PPP3R1)	OTGQNFJQ	CANB1_HUMAN	Drug Response	[7]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Protein Interaction/Cellular Processes	[15]

Molecular Expression Atlas of This Drug

• The Studied Disease: Graft-versus-host disease
• ICD Disease Classification: 4B24

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Calcineurin (PPP3CA)	DTT	PPP3CA	5.29E-01	1.74E-03	9.99E-03
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.00E-01	2.57E-02	6.18E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.05E-02	4.52E-01	5.39E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.67E-01	-3.83E-03	-1.24E-02
NADPH-cytochrome P450 reductase (CPR)	DME	POR	8.69E-02	-1.76E-01	-3.46E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tacrolimus

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Azathioprine.	Transplant rejection [NE84]	[21]

Coadministration of a Drug Treating the Disease Different from Tacrolimus (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Tacrolimus caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[21]
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Tacrolimus due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[22]
Repaglinide	DM5SXUV	Moderate	Increased plasma concentrations of Tacrolimus and Repaglinide due to competitive inhibition of the same metabolic pathway.	Acute diabete complication [5A2Y]	[22]
Pioglitazone	DMKJ485	Moderate	Increased plasma concentrations of Tacrolimus and Pioglitazone due to competitive inhibition of the same metabolic pathway.	Acute diabete complication [5A2Y]	[22]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Ivosidenib.	Acute myeloid leukaemia [2A60]	[23]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Midostaurin.	Acute myeloid leukaemia [2A60]	[24]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[25]
Arn-509	DMT81LZ	Major	Increased metabolism of Tacrolimus caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Gilteritinib.	Acute myeloid leukaemia [2A60]	[27]
Oliceridine	DM6MDCF	Moderate	Increased plasma concentrations of Tacrolimus and Oliceridine due to competitive inhibition of the same metabolic pathway.	Acute pain [MG31]	[22]
Framycetin	DMF8DNE	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Framycetin.	Alcoholic liver disease [DB94]	[22]
Metronidazole	DMTIVEN	Moderate	Decreased metabolism of Tacrolimus caused by Metronidazole mediated inhibition of CYP450 enzyme.	Amoebiasis [1A36]	[28]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Inotersen.	Amyloidosis [5D00]	[29]
Siltuximab	DMGEATB	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Siltuximab.	Anemia [3A00-3A9Z]	[29]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Ivabradine.	Angina pectoris [BA40]	[29]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Bepridil.	Angina pectoris [BA40]	[24]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Dronedarone.	Angina pectoris [BA40]	[24]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Tacrolimus caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[30]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[31]
Cilostazol	DMZMSCT	Moderate	Increased plasma concentrations of Tacrolimus and Cilostazol due to competitive inhibition of the same metabolic pathway.	Arterial occlusive disease [BD40]	[22]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Tacrolimus caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[32]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Levalbuterol.	Asthma [CA23]	[33]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Terbutaline.	Asthma [CA23]	[34]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Pirbuterol.	Asthma [CA23]	[34]
Budesonide	DMJIBAW	Moderate	Increased plasma concentrations of Tacrolimus and Budesonide due to competitive inhibition of the same metabolic pathway.	Asthma [CA23]	[22]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Salbutamol.	Asthma [CA23]	[33]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Roflumilast.	Asthma [CA23]	[29]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Formoterol.	Asthma [CA23]	[34]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[29]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[24]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Kanamycin	DM2DMPO	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Kanamycin.	Bacterial infection [1A00-1C4Z]	[22]
Tindamax	DM3OWT4	Moderate	Decreased metabolism of Tacrolimus caused by Tindamax mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Tacrolimus caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of nephrotoxicity by the combination of Tacrolimus and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[21]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Streptomycin	DME1LQN	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Streptomycin.	Bacterial infection [1A00-1C4Z]	[22]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Tacrolimus and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[37]
Netilmicin	DMRD1QK	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Netilmicin.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Troleandomycin	DMUZNIG	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Troleandomycin.	Bacterial infection [1A00-1C4Z]	[38]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Retigabine.	Behcet disease [4A62]	[24]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Tacrolimus caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[39]
Etidronic acid	DM1XHYJ	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Etidronic acid.	Bone paget disease [FB85]	[22]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Tacrolimus caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[21]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Eribulin.	Breast cancer [2C60-2C6Y]	[24]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[40]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Lapatinib.	Breast cancer [2C60-2C6Y]	[24]
Exemestane	DM9HPW3	Moderate	Increased plasma concentrations of Tacrolimus and Exemestane due to competitive inhibition of the same metabolic pathway.	Breast cancer [2C60-2C6Y]	[22]
Tucatinib	DMBESUA	Major	Decreased metabolism of Tacrolimus caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Tacrolimus caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[21]
Letrozole	DMH07Y3	Moderate	Increased plasma concentrations of Tacrolimus and Letrozole due to competitive inhibition of the same metabolic pathway.	Breast cancer [2C60-2C6Y]	[22]
Quinestrol	DMJ6H1Z	Moderate	Increased plasma concentrations of Tacrolimus and Quinestrol due to competitive inhibition of the same metabolic pathway.	Breast cancer [2C60-2C6Y]	[22]
Cabazitaxel	DMPAZHC	Moderate	Increased plasma concentrations of Tacrolimus and Cabazitaxel due to competitive inhibition of the same metabolic pathway.	Breast cancer [2C60-2C6Y]	[22]
Bosutinib	DMTI8YE	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Bosutinib.	Breast cancer [2C60-2C6Y]	[29]
Atorvastatin	DMF28YC	Moderate	Increased plasma concentrations of Tacrolimus and Atorvastatin due to competitive inhibition of the same metabolic pathway.	Cardiovascular disease [BA00-BE2Z]	[41]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Iodipamide.	Cholelithiasis [DC11]	[42]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[43]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[33]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Dihydrocodeine	DMB0FWL	Moderate	Increased plasma concentrations of Tacrolimus and Dihydrocodeine due to competitive inhibition of the same metabolic pathway.	Chronic pain [MG30]	[22]
Ketoprofen	DMRKXPT	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Ketoprofen.	Chronic pain [MG30]	[22]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Tacrolimus due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[44]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Isoproterenol.	Conduction disorder [BC63]	[33]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Tacrolimus and Drospirenone.	Contraceptive management [QA21]	[45]
Levonorgestrel	DM1DP7T	Moderate	Increased plasma concentrations of Tacrolimus and Levonorgestrel due to competitive inhibition of the same metabolic pathway.	Contraceptive management [QA21]	[22]
Levobupivacaine	DM783CH	Moderate	Increased plasma concentrations of Tacrolimus and Levobupivacaine due to competitive inhibition of the same metabolic pathway.	Corneal disease [9A76-9A78]	[22]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Sevoflurane.	Corneal disease [9A76-9A78]	[24]
Methoxyflurane	DML0RAE	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Methoxyflurane.	Corneal disease [9A76-9A78]	[22]
Cocaine	DMSOX7I	Moderate	Increased plasma concentrations of Tacrolimus and Cocaine due to competitive inhibition of the same metabolic pathway.	Corneal disease [9A76-9A78]	[22]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Probucol.	Coronary atherosclerosis [BA80]	[24]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Pasireotide.	Cushing syndrome [5A70]	[24]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Osilodrostat.	Cushing syndrome [5A70]	[29]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Tacrolimus caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[21]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[46]
MK-8228	DMOB58Q	Major	Decreased metabolism of Tacrolimus caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[47]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Tacrolimus caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[48]
Sertraline	DM0FB1J	Moderate	Increased plasma concentrations of Tacrolimus and Sertraline due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Cyclobenzaprine	DM1YBRM	Moderate	Increased plasma concentrations of Tacrolimus and Cyclobenzaprine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Tacrolimus caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Escitalopram.	Depression [6A70-6A7Z]	[24]
OPC-34712	DMHG57U	Moderate	Increased plasma concentrations of Tacrolimus and OPC-34712 due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[22]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Clomipramine.	Depression [6A70-6A7Z]	[24]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Doxepin.	Depression [6A70-6A7Z]	[24]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Maprotiline.	Depression [6A70-6A7Z]	[24]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[24]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Deutetrabenazine.	Dystonic disorder [8A02]	[49]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Ingrezza.	Dystonic disorder [8A02]	[50]
Zonisamide	DM0DTF7	Moderate	Increased plasma concentrations of Tacrolimus and Zonisamide due to competitive inhibition of the same metabolic pathway.	Epilepsy/seizure [8A61-8A6Z]	[22]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Tacrolimus caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Tacrolimus caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Tiagabine	DMKSQG0	Moderate	Increased plasma concentrations of Tacrolimus and Tiagabine due to competitive inhibition of the same metabolic pathway.	Epilepsy/seizure [8A61-8A6Z]	[22]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Tacrolimus caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Fosphenytoin	DMOX3LB	Major	Accelerated clearance of Tacrolimus due to the transporter induction by Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[26]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Tacrolimus caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Tacrolimus caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[21]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Solifenacin.	Functional bladder disorder [GC50]	[24]
Tolterodine	DMSHPW8	Moderate	Increased plasma concentrations of Tacrolimus and Tolterodine due to competitive inhibition of the same metabolic pathway.	Functional bladder disorder [GC50]	[22]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Tacrolimus caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[32]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Tacrolimus caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[52]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Tacrolimus caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[32]
Ripretinib	DM958QB	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[21]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[24]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Tacrolimus caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[21]
Digitoxin	DMWVIGP	Moderate	Increased plasma concentrations of Tacrolimus and Digitoxin due to competitive inhibition of the same metabolic pathway.	Heart failure [BD10-BD1Z]	[22]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Tacrolimus caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[21]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Tacrolimus caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[21]
Telaprevir	DMMRV29	Major	Decreased clearance of Tacrolimus due to the transporter inhibition by Telaprevir.	Hepatitis virus infection [1E50-1E51]	[21]
177Lu-DOTATATE	DMT8GVU	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[22]
Rifampin	DMA8J1G	Major	Accelerated clearance of Tacrolimus due to the transporter induction by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Rifapentine	DMCHV4I	Major	Increased metabolism of Tacrolimus caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[53]
MK-1439	DM215WE	Minor	Increased metabolism of Tacrolimus caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Tacrolimus caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Tacrolimus caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Tipranavir	DM8HJX6	Moderate	Accelerated clearance of Tacrolimus due to the transporter induction by Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Tacrolimus caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Darunavir	DMN3GCH	Major	Decreased metabolism of Tacrolimus caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Tacrolimus caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Tacrolimus and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[57]
Eprosartan	DM07K2I	Moderate	Increased risk of hyperkalemia by the combination of Tacrolimus and Eprosartan.	Hypertension [BA00-BA04]	[58]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[24]
Captopril	DM458UM	Moderate	Increased risk of hyperkalemia by the combination of Tacrolimus and Captopril.	Hypertension [BA00-BA04]	[58]
TAK-491	DMCF6SX	Moderate	Increased risk of hyperkalemia by the combination of Tacrolimus and TAK-491.	Hypertension [BA00-BA04]	[58]
Felodipine	DMOSW35	Moderate	Increased plasma concentrations of Tacrolimus and Felodipine due to competitive inhibition of the same metabolic pathway.	Hypertension [BA00-BA04]	[22]
Quinapril	DMR8H31	Moderate	Decreased absorption of Tacrolimus due to formation of complexes caused by Quinapril.	Hypertension [BA00-BA04]	[29]
Telmisartan	DMS3GX2	Moderate	Increased risk of hyperkalemia by the combination of Tacrolimus and Telmisartan.	Hypertension [BA00-BA04]	[58]
Irbesartan	DMTP1DC	Moderate	Increased risk of hyperkalemia by the combination of Tacrolimus and Irbesartan.	Hypertension [BA00-BA04]	[58]
Conivaptan	DM1V329	Major	Decreased metabolism of Tacrolimus caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[32]
Givosiran	DM5PFIJ	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[22]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Tacrolimus caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[59]
Balsalazide	DM7I1T9	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Balsalazide.	Indeterminate colitis [DD72]	[22]
Meclofenamic acid	DM05FXR	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[22]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tacrolimus caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[21]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Tacrolimus caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[21]
Triazolam	DMETYK5	Moderate	Increased plasma concentrations of Tacrolimus and Triazolam due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[22]
Zaleplon	DMGFWSM	Moderate	Increased plasma concentrations of Tacrolimus and Zaleplon due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[22]
ITI-007	DMUQ1DO	Moderate	Increased plasma concentrations of Tacrolimus and ITI-007 due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[22]
Quazepam	DMY4D87	Moderate	Increased plasma concentrations of Tacrolimus and Quazepam due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[22]
Estazolam	DMZGXUM	Moderate	Increased plasma concentrations of Tacrolimus and Estazolam due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[22]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[29]
Naloxegol	DML0B41	Minor	Decreased clearance of Tacrolimus due to the transporter inhibition by Naloxegol.	Large intestine motility disorder [DB32]	[60]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Tacrolimus caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[29]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Denosumab.	Low bone mass disorder [FB83]	[61]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Crizotinib.	Lung cancer [2C25]	[62]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Tacrolimus caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[21]
Ceritinib	DMB920Z	Major	Decreased metabolism of Tacrolimus caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tacrolimus caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[63]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Tacrolimus caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[29]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[64]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Selpercatinib.	Lung cancer [2C25]	[29]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Lumefantrine.	Malaria [1F40-1F45]	[21]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Halofantrine.	Malaria [1F40-1F45]	[65]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Primaquine.	Malaria [1F40-1F45]	[24]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[29]
Idelalisib	DM602WT	Major	Decreased metabolism of Tacrolimus caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[32]
GDC-0199	DMH0QKA	Major	Decreased clearance of Tacrolimus due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[21]
Moxetumomab pasudotox	DMN63DZ	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Moxetumomab pasudotox.	Mature B-cell leukaemia [2A82]	[22]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Tacrolimus caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[21]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[66]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Tacrolimus caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[67]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[29]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[21]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Vemurafenib.	Melanoma [2C30]	[24]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and LGX818.	Melanoma [2C30]	[68]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tacrolimus caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[21]
Ethinyl estradiol	DMODJ40	Moderate	Increased plasma concentrations of Tacrolimus and Ethinyl estradiol due to competitive inhibition of the same metabolic pathway.	Menopausal disorder [GA30]	[22]
Danazol	DML8KTN	Moderate	Decreased metabolism of Tacrolimus caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[22]
Almogran	DM7I64Z	Moderate	Increased plasma concentrations of Tacrolimus and Almogran due to competitive inhibition of the same metabolic pathway.	Migraine [8A80]	[22]
Rimegepant	DMHOAUG	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Rimegepant.	Migraine [8A80]	[69]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Exjade.	Mineral absorption/transport disorder [5C64]	[70]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Tacrolimus due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[24]
Gallium nitrate	DMF9O6B	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Gallium nitrate.	Mineral excesses [5B91]	[22]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Panobinostat.	Multiple myeloma [2A83]	[71]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Thalidomide.	Multiple myeloma [2A83]	[21]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Tecfidera.	Multiple sclerosis [8A40]	[72]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Tacrolimus and Siponimod.	Multiple sclerosis [8A40]	[21]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Tacrolimus and Fingolimod.	Multiple sclerosis [8A40]	[73]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Ocrelizumab.	Multiple sclerosis [8A40]	[74]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Tacrolimus and Ozanimod.	Multiple sclerosis [8A40]	[29]
Deflazacort	DMV0RNS	Moderate	Increased plasma concentrations of Tacrolimus and Deflazacort due to competitive inhibition of the same metabolic pathway.	Muscular dystrophy [8C70]	[22]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Romidepsin.	Mycosis fungoides [2B01]	[24]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Tacrolimus caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[21]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Nilotinib.	Myeloproliferative neoplasm [2A20]	[24]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Dasatinib.	Myeloproliferative neoplasm [2A20]	[75]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[76]
Busulfan	DMXYJ9C	Moderate	Increased plasma concentrations of Tacrolimus and Busulfan due to competitive inhibition of the same metabolic pathway.	Myeloproliferative neoplasm [2A20]	[22]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Promethazine.	Nausea/vomiting [MD90]	[24]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Tacrolimus caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[21]
Metoclopramide	DMFA5MY	Moderate	Altered absorption of Tacrolimus due to GI dynamics variation caused by Metoclopramide.	Nausea/vomiting [MD90]	[77]
Granisetron	DMIUW25	Moderate	Increased plasma concentrations of Tacrolimus and Granisetron due to competitive inhibition of the same metabolic pathway.	Nausea/vomiting [MD90]	[22]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Ondansetron.	Nausea/vomiting [MD90]	[24]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Entrectinib.	Non-small cell lung cancer [2C25]	[21]
Sibutramine	DMFJTDI	Moderate	Increased plasma concentrations of Tacrolimus and Sibutramine due to competitive inhibition of the same metabolic pathway.	Obesity [5B80-5B81]	[22]
Benzphetamine	DMIJATC	Moderate	Increased plasma concentrations of Tacrolimus and Benzphetamine due to competitive inhibition of the same metabolic pathway.	Obesity [5B80-5B81]	[22]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Levomethadyl Acetate.	Opioid use disorder [6C43]	[29]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Lofexidine.	Opioid use disorder [6C43]	[24]
S-297995	DM26IH8	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by S-297995.	Opioid use disorder [6C43]	[29]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Rucaparib.	Ovarian cancer [2C73]	[24]
Ibuprofen	DM8VCBE	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Ibuprofen.	Pain [MG30-MG3Z]	[22]
Buprenorphine	DMPRI8G	Moderate	Increased plasma concentrations of Tacrolimus and Buprenorphine due to competitive inhibition of the same metabolic pathway.	Pain [MG30-MG3Z]	[22]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Triclabendazole.	Parasitic worm infestation [1F90]	[24]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Pimavanserin.	Parkinsonism [8A00]	[78]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Tacrolimus caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[21]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tacrolimus caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[79]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Famotidine.	Peptic ulcer [DA61]	[21]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[80]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Lefamulin.	Pneumonia [CA40]	[81]
Bromfenac	DMKB79O	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Bromfenac.	Postoperative inflammation [1A00-CA43]	[22]
Ergonovine	DM0VEC1	Moderate	Increased plasma concentrations of Tacrolimus and Ergonovine due to competitive inhibition of the same metabolic pathway.	Postpartum haemorrhage [JA43]	[22]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Tacrolimus caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[32]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Ritodrine.	Preterm labour/delivery [JB00]	[34]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Degarelix.	Prostate cancer [2C82]	[29]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and ABIRATERONE.	Prostate cancer [2C82]	[29]
Enzalutamide	DMGL19D	Major	Increased metabolism of Tacrolimus caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[26]
Relugolix	DMK7IWL	Major	Decreased clearance of Tacrolimus due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[82]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Tacrolimus caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[21]
Silodosin	DMJSBT6	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Silodosin.	Prostate hyperplasia [GA90]	[83]
Dutasteride	DMQ4TJK	Moderate	Increased plasma concentrations of Tacrolimus and Dutasteride due to competitive inhibition of the same metabolic pathway.	Prostate hyperplasia [GA90]	[22]
Finasteride	DMWV3TZ	Moderate	Increased plasma concentrations of Tacrolimus and Finasteride due to competitive inhibition of the same metabolic pathway.	Prostate hyperplasia [GA90]	[22]
Ustekinumab	DMHTYK3	Moderate	Additive myelosuppressive effects by the combination of Tacrolimus and Ustekinumab.	Psoriasis [EA90]	[29]
Tildrakizumab	DMLW9HG	Moderate	Additive myelosuppressive effects by the combination of Tacrolimus and Tildrakizumab.	Psoriasis [EA90]	[29]
Risankizumab	DMM32GT	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Risankizumab.	Psoriasis [EA90]	[29]
Ixekizumab	DMXW92T	Moderate	Additive myelosuppressive effects by the combination of Tacrolimus and Ixekizumab.	Psoriasis [EA90]	[29]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Levomepromazine.	Psychotic disorder [6A20-6A25]	[24]
Riociguat	DMXBLMP	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[21]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[84]
Colistimethate	DMZ9BMU	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Colistimethate.	Respiratory infection [CA07-CA4Z]	[22]
Salsalate	DM13P4C	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Salsalate.	Rheumatoid arthritis [FA20]	[22]
Tocilizumab	DM7J6OR	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Tocilizumab.	Rheumatoid arthritis [FA20]	[29]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Tacrolimus and Canakinumab.	Rheumatoid arthritis [FA20]	[29]
Rilonacept	DMGLUQS	Moderate	Additive myelosuppressive effects by the combination of Tacrolimus and Rilonacept.	Rheumatoid arthritis [FA20]	[29]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Tacrolimus and Golimumab.	Rheumatoid arthritis [FA20]	[85]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Tacrolimus caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[21]
Sarilumab	DMOGNXY	Moderate	Additive myelosuppressive effects by the combination of Tacrolimus and Sarilumab.	Rheumatoid arthritis [FA20]	[29]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Tacrolimus and Leflunomide.	Rheumatoid arthritis [FA20]	[57]
Quetiapine	DM1N62C	Moderate	Increased plasma concentrations of Tacrolimus and Quetiapine due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[22]
Aripiprazole	DM3NUMH	Moderate	Increased plasma concentrations of Tacrolimus and Aripiprazole due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[22]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Iloperidone.	Schizophrenia [6A20]	[24]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Paliperidone.	Schizophrenia [6A20]	[24]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Amisulpride.	Schizophrenia [6A20]	[86]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Asenapine.	Schizophrenia [6A20]	[24]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Pimozide.	Schizophrenia [6A20]	[29]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Tacrolimus when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[87]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Tacrolimus caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[21]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Tacrolimus caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[29]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Tacrolimus caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
Methylprednisolone	DM4BDON	Moderate	Increased plasma concentrations of Tacrolimus and Methylprednisolone due to competitive inhibition of the same metabolic pathway.	Solid tumour/cancer [2A00-2F9Z]	[22]
Ifosfamide	DMCT3I8	Moderate	Increased plasma concentrations of Tacrolimus and Ifosfamide due to competitive inhibition of the same metabolic pathway.	Solid tumour/cancer [2A00-2F9Z]	[22]
Docetaxel	DMDI269	Moderate	Increased plasma concentrations of Tacrolimus and Docetaxel due to competitive inhibition of the same metabolic pathway.	Solid tumour/cancer [2A00-2F9Z]	[22]
Armodafinil	DMGB035	Moderate	Increased metabolism of Tacrolimus caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[24]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[24]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[29]
Taxol	DMUOT9V	Moderate	Increased plasma concentrations of Tacrolimus and Taxol due to competitive inhibition of the same metabolic pathway.	Solid tumour/cancer [2A00-2F9Z]	[22]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Telavancin	DM58VQX	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[22]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Tacrolimus caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[21]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[88]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[89]
Apixaban	DM89JLN	Moderate	Decreased clearance of Tacrolimus due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[29]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Tacrolimus caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[29]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Lenvatinib.	Thyroid cancer [2D10]	[24]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Cabozantinib.	Thyroid cancer [2D10]	[29]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Papaverine.	Tonus and reflex abnormality [MB47]	[90]
Olsalazine	DMZW9HA	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Olsalazine.	Ulcerative colitis [DD71]	[22]
Plazomicin	DMKMBES	Major	Increased risk of nephrotoxicity by the combination of Tacrolimus and Plazomicin.	Urinary tract infection [GC08]	[22]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Tacrolimus caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[21]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[91]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Procainamide.	Ventricular tachyarrhythmia [BC71]	[24]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Propafenone.	Ventricular tachyarrhythmia [BC71]	[24]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Tacrolimus and Flecainide.	Ventricular tachyarrhythmia [BC71]	[24]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Tacrolimus and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[24]
Ganciclovir	DM1MBYQ	Moderate	Increased risk of nephrotoxicity by the combination of Tacrolimus and Ganciclovir.	Virus infection [1A24-1D9Z]	[21]
Valganciclovir	DMS2IUH	Moderate	Increased risk of lowers seizure threshold by the combination of Tacrolimus and Valganciclovir.	Virus infection [1A24-1D9Z]	[21]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tacrolimus 0.75 mg tablet	0.75 mg	24 HR Extended Release Oral Tablet	Oral
Tacrolimus 1 mg tablet	1 mg	24 HR Extended Release Oral Tablet	Oral
Tacrolimus 4 mg tablet	4 mg	24 HR Extended Release Oral Tablet	Oral
Tacrolimus 1 mg capsule	1 mg	Oral Capsule	Oral
Tacrolimus 0.5 mg capsule	0.5 mg	Oral Capsule	Oral
Tacrolimus 5 mg capsule	5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Tacrolimus FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6784).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN: Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One. 2018 Apr 11;13(4):e0195764. doi: 10.1371/journal.pone.0195764. eCollection 2018.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [8] Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
• [9] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [10] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [11] Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
• [12] Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
• [13] High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
• [14] Calcineurin is an important factor involved in glucose uptake in human adipocytes. Mol Cell Biochem. 2018 Aug;445(1-2):157-168. doi: 10.1007/s11010-017-3261-0. Epub 2018 Jan 27.
• [15] Immunosuppressive calcineurin inhibitor cyclosporine A?induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022 Mar;298(3):101589. doi: 10.1016/j.jbc.2022.101589. Epub 2022 Jan 14.
• [16] Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002 Aug 27;74(4):571-2. doi: 10.1097/00007890-200208270-00024.
• [17] CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
• [18] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [19] Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005 Jun;152(6):1173-81. doi: 10.1111/j.1365-2133.2005.06474.x.
• [20] GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. Toxicol Sci. 2012 Jun;127(2):425-37. doi: 10.1093/toxsci/kfs108. Epub 2012 Mar 12.
• [21] Cerner Multum, Inc. "Australian Product Information.".
• [22] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [23] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [24] Canadian Pharmacists Association.
• [25] Multum Information Services, Inc. Expert Review Panel.
• [26] Bhaloo S, Prasad GV "Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report." Transplant Proc 35 (2003): 2449-51. [PMID: 14611983]
• [27] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [28] Herzig K, Johnson DW "Marked elevation of blood cyclosporine and tacrolimus levels due to concurrent metronidazole therapy." Nephrol Dial Transplant 14 (1999): 521-3. [PMID: 10069238]
• [29] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [30] Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins R "Nifedipine interaction with tacrolimus in liver transplant recipients." Ann Pharmacother 31 (1997): 571-5. [PMID: 9161650]
• [31] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [32] Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
• [33] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [34] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [35] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [36] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
• [37] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
• [38] Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
• [39] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [40] Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [41] Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
• [42] Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
• [43] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [44] Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
• [45] Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
• [46] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [47] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [48] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [49] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [50] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [51] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [52] Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
• [53] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [54] Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol 23 (2009): 423-5. [PMID: 19709321]
• [55] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [56] Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
• [57] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [58] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
• [59] Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [60] Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [61] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [62] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [63] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [64] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [65] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [66] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [67] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [68] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [69] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [70] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [71] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [72] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [73] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [74] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [75] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [76] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [77] Prescott WA Jr, Callahan BL, Park JM "Tacrolimus toxicity associated with concomitant metoclopramide therapy." Pharmacotherapy 24 (2004): 532-7. [PMID: 15098810]
• [78] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [79] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [80] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [81] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [82] Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
• [83] Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
• [84] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [85] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [86] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [87] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [88] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [89] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [90] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [91] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]